[go: up one dir, main page]

BR0209290A - Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh - Google Patents

Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh

Info

Publication number
BR0209290A
BR0209290A BR0209290-5A BR0209290A BR0209290A BR 0209290 A BR0209290 A BR 0209290A BR 0209290 A BR0209290 A BR 0209290A BR 0209290 A BR0209290 A BR 0209290A
Authority
BR
Brazil
Prior art keywords
dementia
treatment
neurodegenerative diseases
lhrh antagonists
intermediate doses
Prior art date
Application number
BR0209290-5A
Other languages
English (en)
Inventor
Juergen Engel
Rainer Voegeli
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of BR0209290A publication Critical patent/BR0209290A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"TRATAMENTO DE DEMêNCIA E DOENçAS NEURODEGENERATIVAS COM DOSES INTERMEDIáRIAS DE ANTAGONISTAS DE LHRH". A presente invenção refere-se ao tratamento de demência e doenças neurodegenerativas semelhantes à doença de Alzheimer com doses intermediárias de antagonistas de LHRH, as quais não causam uma castração. Um antagonista de LHRH preferido é cetrorelix.
BR0209290-5A 2001-04-30 2002-04-27 Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh BR0209290A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28743401P 2001-04-30 2001-04-30
PCT/EP2002/004677 WO2002102401A1 (en) 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Publications (1)

Publication Number Publication Date
BR0209290A true BR0209290A (pt) 2004-07-13

Family

ID=23102886

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209290-5A BR0209290A (pt) 2001-04-30 2002-04-27 Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh

Country Status (27)

Country Link
US (1) US7288517B2 (pt)
EP (1) EP1392348B1 (pt)
JP (1) JP2004529207A (pt)
KR (1) KR20040000446A (pt)
CN (1) CN1317030C (pt)
AT (1) ATE400287T1 (pt)
AU (1) AU2002310788B2 (pt)
BG (1) BG108339A (pt)
BR (1) BR0209290A (pt)
CA (1) CA2444876A1 (pt)
CZ (1) CZ20033167A3 (pt)
DE (1) DE60227507D1 (pt)
DK (1) DK1392348T3 (pt)
ES (1) ES2307760T3 (pt)
HU (1) HUP0400067A2 (pt)
IL (1) IL156777A0 (pt)
MX (1) MXPA03008666A (pt)
NO (1) NO20034322L (pt)
NZ (1) NZ544417A (pt)
PL (1) PL362319A1 (pt)
PT (1) PT1392348E (pt)
RU (1) RU2319501C2 (pt)
SI (1) SI1392348T1 (pt)
SK (1) SK14512003A3 (pt)
UA (1) UA80679C2 (pt)
WO (1) WO2002102401A1 (pt)
ZA (1) ZA200305326B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
DK1300398T3 (da) 2000-07-05 2006-07-17 Astellas Pharma Inc Propan-1,3-dionderivat
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
MXPA06014131A (es) * 2004-06-04 2007-03-07 Astellas Pharma Inc Derivado de propano-1,3-diona o su sal.
AU2005322611A1 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of Alzheimer's disease
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
CA2603185C (en) 2005-03-31 2011-07-26 Astellas Pharma Inc. Propane-1,3-dione derivative or salt thereof
AU2007312165A1 (en) * 2006-10-21 2008-04-24 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
KR20100057054A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 터프친의 용도
JP2010538997A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 肺炎連鎖球菌感染の治療における治療剤としての、フィブリノゲン受容体アンタゴニストおよび／またはゴナドトロピン放出ペプチドの使用
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
CA2726247C (en) * 2008-05-29 2018-06-26 Isr Immune System Regulation Ab Method and means for treating viral disease, in particular hiv/aids
JP5998142B2 (ja) 2010-09-27 2016-09-28 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのその使用
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
WO2025155903A1 (en) * 2024-01-19 2025-07-24 Temple University-Of The Commonwealth System Of Higher Education Compositions of antioxidant translation modulators for treating neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) * 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
WO1997044339A1 (en) 1996-05-20 1997-11-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19911771B4 (de) 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
KR20020039266A (ko) * 1999-05-14 2002-05-25 추후기재 고나도트로핀 방출 호르몬 수용체 길항제로서의 이미다조-및 피롤로［1,2-ａ］피리미드-4-온
CA2309395A1 (en) * 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
JP2003512379A (ja) 1999-10-15 2003-04-02 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストおよびそれに関連する方法
EP1393747A4 (en) 2000-04-13 2004-03-03 Takeda Chemical Industries Ltd AGENT FOR PREVENTION / TREATMENT OF ALZHEIMER DISEASE
DK1300398T3 (da) 2000-07-05 2006-07-17 Astellas Pharma Inc Propan-1,3-dionderivat

Also Published As

Publication number Publication date
EP1392348A1 (en) 2004-03-03
PL362319A1 (en) 2004-10-18
CN1575185A (zh) 2005-02-02
ATE400287T1 (de) 2008-07-15
NO20034322D0 (no) 2003-09-26
HUP0400067A2 (hu) 2004-04-28
PT1392348E (pt) 2008-09-09
RU2319501C2 (ru) 2008-03-20
DK1392348T3 (da) 2008-09-29
KR20040000446A (ko) 2004-01-03
BG108339A (bg) 2004-11-30
HK1072000A1 (en) 2005-08-12
MXPA03008666A (es) 2004-10-15
DE60227507D1 (de) 2008-08-21
SK14512003A3 (sk) 2004-08-03
US7288517B2 (en) 2007-10-30
NO20034322L (no) 2003-09-26
ZA200305326B (en) 2003-07-30
ES2307760T3 (es) 2008-12-01
IL156777A0 (en) 2004-02-08
AU2002310788B2 (en) 2007-04-05
CN1317030C (zh) 2007-05-23
UA80679C2 (en) 2007-10-25
JP2004529207A (ja) 2004-09-24
CA2444876A1 (en) 2002-12-27
CZ20033167A3 (cs) 2004-08-18
NZ544417A (en) 2008-03-28
WO2002102401A1 (en) 2002-12-27
US20020177556A1 (en) 2002-11-28
RU2003134949A (ru) 2005-02-10
SI1392348T1 (sl) 2008-12-31
EP1392348B1 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
BR0209290A (pt) Tratamento de demência e doenças neurodegenerativas com doses intermediárias de antagonistas de lhrh
NO20071560L (no) Vasopressin v1a-antagonister.
GB0129260D0 (en) Pharmaceutical compositions and their uses
LU92854I2 (fr) Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil
GB0108592D0 (en) Therapeutic agents
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
BR0307998A (pt) Hidroxietilaminas substituìdas
BR9408063A (pt) Antagonistas de receptores de taquicinina que nÆo sÆo pept¡deos
GB0223040D0 (en) Therapeutic compounds
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
MA28106A1 (fr) Compositions immunogenes
BR0206495A (pt) Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
BR0110383A (pt) Peptìdeo modulador de receptor de trombopoietina
MXPA04003298A (es) Compuestos de piperidina como antagonistas muscarinicos.
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
ZA200700945B (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
ATA8192003A (de) Verwendung von oxicam-verbindungen
WO2003100433A3 (en) Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (avpr3)
WO2003090771A3 (en) Diagnostics and therapeutics for diseases associated with trace amine receptor 3(ta3)
WO2004057328A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor 38 (gpr38)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.